Varied Effects of Atypical Neuroleptics on P50 Auditory Gating in Schizophrenia Patients
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Sensory gating deficits found in schizophrenia can be assessed by using a paired auditory stimulus paradigm to measure auditory evoked response. The ratio of the P50 response amplitude of the second or test stimulus to that of the first or conditioning stimulus is expressed as a percentage. Normal subjects generally suppress the second response and typically have ratios of less than 40%. Subjects with schizophrenia and half their first-degree relatives have deficits in sensory gating, with P50 ratios that are generally greater than 50%. Treatment with typical neuroleptics does not reverse this deficit. However, previous studies have shown that treatment with clozapine, an atypical neuroleptic, ameliorates this deficit in clinically responsive patients. This study sought to determine whether other atypical neuroleptics improve P50 ratios. METHOD: P50 evoked potential recordings were obtained from 132 patients with schizophrenia and 177 healthy comparison subjects. Eighty-eight patients were being treated with atypical neuroleptics (clozapine [N=26], olanzapine [N=31], risperidone [N=22], and quetiapine [N=9]). Thirty-four patients were taking typical neuroleptics, and 10 were unmedicated. RESULTS: Healthy subjects exhibited P50 suppression that was significantly better than the schizophrenia patients receiving typical neuroleptics (mean=19.8% [SD=21.0%] versus 110.1% [SD=87.9%]). Patients receiving atypical neuroleptics had a mean P50 ratio that fell between these two means (mean=70.4%, SD=53.7%). When patients treated with different atypical neuroleptics were compared, only the clozapine group had mean P50 ratios that were in the normal range. All other groups exhibited auditory P50 response inhibition that was significantly poorer than that of the healthy subjects. CONCLUSIONS: Improvement in P50 gating appears to be greatest in patients treated with clozapine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141
Self-citationNeurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia
Cullum, C. M., Harris, J. G., Waldo, M. C., Smernoff, E., Madison, A., Nagamoto, H. T., Griffith, J., Adler, L. E., & Freedman, R. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90048-n · Cited by 212
Self-citation
Cited by
Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report
Ziedonis, D., Hitsman, B., Beckham, J. C., Zvolensky, M., Adler, L. E., Audrain-McGovern, J., Breslau, N., Brown, R. A., George, T. P., Williams, J., et al. (2008) · Nicotine & Tobacco Research · doi:10.1080/14622200802443569 · Cited by 735
Self-citationNeurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Turetsky, B. I., Calkins, M. E., Light, G. A., Olincy, A., Radant, A. D., & Swerdlow, N. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl060 · Cited by 567
Self-citationProof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
Olincy, A., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S., Stevens, K. E., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.630 · Cited by 527
Self-citationInitial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426
Self-citationGreenwood, T. A., Braff, D. L., Light, G. A., Cadenhead, K. S., Calkins, M. E., Dobie, D. J., Freedman, R., Green, M. F., Gur, R. E., Gur, R. C., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.11.1242 · Cited by 381
Self-citationP50 sensory gating ratios in schizophrenics and controls: A review and data analysis
Patterson, J. V., Hetrick, W. P., Boutros, N. N., Jin, Y., Sandman, C., Stern, H., Potkin, S., & Bunney, W. E. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.02.009 · Cited by 352
Neurophysiological biomarkers for drug development in schizophrenia
Javitt, D. C., Spencer, K. M., Thaker, G. K., Winterer, G., & Hajós, M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2463 · Cited by 342
Review of Clinical Correlates of P50 Sensory Gating Abnormalities in Patients with Schizophrenia
Potter, D., Summerfelt, A., Gold, J., & Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj050 · Cited by 259
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
Self-citationTregellas, J. R., Davalos, D. B., Rojas, D. C., Waldo, M. C., Gibson, L., Wylie, K., Du, Y. P., & Freedman, R. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.12.033 · Cited by 143
“The P50 potential was identified and measured by using a previously described computer algorithm (Adler et al., 2004).”
MethodSelf-citationSensory gating endophenotype based on its neural oscillatory pattern and heritability estimate
Hong, L. E., Summerfelt, A., Mitchell, B. D., McMahon, R. P., Wonodi, I., Buchanan, R. W., & Thaker, G. K. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.9.1008 · Cited by 115
The role of cortical inhibition in the pathophysiology and treatment of schizophrenia
Daskalakis, Z. J., Fitzgerald, P. B., & Christensen, B. K. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.006 · Cited by 111
Kenemans, J. L., & Kähkönen, S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.157 · Cited by 104
“Clozapine’s interactions with the 5-HT3 receptor have also been linked to the enhancement of a-7-nicotinergically mediated ACh transmission (Adler et al, 2004).”
Predictive coding in autism spectrum disorder and attention deficit hyperactivity disorder
Gonzalez-Gadea, M. L., Chennu, S., Bekinschtein, T. A., Rattazzi, A., Beraudi, A., Tripicchio, P., Moyano, B., Soffita, Y., Steinberg, L., Adolfi, F., et al. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00543.2015 · Cited by 100
Distinct neural generators of sensory gating in schizophrenia
Williams, T. J., Nuechterlein, K. H., Subotnik, K. L., & Yee, C. M. (2011) · Psychophysiology · doi:10.1111/j.1469-8986.2010.01119.x · Cited by 67
Deficits in auditory P50 inhibition in obsessive-compulsive disorder
Hashimoto, T., Shimizu, E., Koike, K., Orita, Y., Suzuki, T., Kanahara, N., Matsuzawa, D., Fukami, G., Miyatake, R., Shinoda, N., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.021 · Cited by 41
Smucny, J., Stevens, K. E., Olincy, A., & Tregellas, J. R. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.77 · Cited by 28
Metadata
- Authors
- Adler, L. E., Olincy, A., Cawthra, E. M., McRae, K. A., Harris, J. G., Nagamoto, H. T., Waldo, M. C., Hall, M.-H., Bowles, A., Woodward, L., Ross, R. G., & Freedman, R.
- Venue
- American Journal of Psychiatry
- Published
- 2004-10-01
- Volume
- 161
- Issue
- 10
- Pages
- 1822-1828
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2128638450
- Cited by
- 197
- References
- 2
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.